
|Videos|February 27, 2017
Medicare Part D and Oncology
Author(s)Lauren Santye, Assistant Editor
Marc O'Connor, COO and chief strategy officer at Curant Health, discusses how the shift to Medicare Part D could impact patients undergoing treatment for cancer.
Advertisement
Marc O'Connor, COO and chief strategy officer at Curant Health, discusses how the shift to Medicare Part D could impact patients undergoing treatment for cancer.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
Medicare Is Finally Covering GLP-1s for Weight Loss: What the Bridge Program Means for Your Practice
2
Updated 2025-2026 COVID-19 Vaccine Nearly Halved ED Visits, Hospitalizations in CDC-Funded Study
3
Beyond Injections: The Rise of Oral GLP-1 Therapy
4
FDA Accepts NDA for Giredestrant in Early-Stage ER-Positive Breast Cancer Under Priority Review
5



















































































































